Plain language summary: the evoke(+) studies of semaglutide for early Alzheimer's disease.

What is this summary about?This article presents a plain language summary of the results from the evoke and evoke+ phase 3 clinical studies, collectively known as the evoke(+) studies, which were published in The Lancet in March 2026.The primary goal of the evoke(+) studies was to understand if oral treatment with up to 14 mg of the drug semaglutide (normally used for the treatment of type 2 diabetes and/or obesity) delayed decline of memory and thinking in people with the early stages of Alzheimer’s disease.A delay in the onset of Alzheimer’s disease has been observed in some previous studies among patients with type 2 diabetes treated with semaglutide, suggesting that this could be a potential treatment for Alzheimer’s disease.The evoke(+) studies compared the effects of semaglutide treatment taken once per day by mouth with a placebo group using clinical tests and blood and cerebral fluid samples that can measure the course of Alzheimer’s disease. People in the trial did not know if they were receiving semaglutide or placebo (e.g. the trials were ‘blinded’).The main test used was change in Clinical Dementia Rating–Sum of Boxes score which assesses thinking, memory, and everyday activities.Change in Alzheimer’s Disease Cooperative Study Activities of Daily Living–Mild Cognitive Impairment score, a measure of activities of daily living in everyday life, was also included in the study. Activities of daily living include those inside and outside the home.What are the key takeaways?Oral semaglutide taken once per day by mouth up to 14 mg did not slow cognitive or functional decline in people with the early stage of Alzheimer’s disease. Therefore, it is not effective as a treatment for the early stages of Alzheimer’s disease.Safety information collected during the studies showed that adverse effects are similar to those observed when semaglutide is taken for other diseases and no new adverse effects were identified.The evoke(+) studies provide information on disease progression and safety that could be used in the future.